'Game changer' experimental drug doubles survival time for pancreatic cancer, trial shows

An observational do drugs that doubles endurance clip for pancreatic malignant neoplastic disease is being hailed as a breakthrough for combating one of the world's deadliest cancers.

A Phase 3, 500-person trial pitted the once-a-day pill against standard chemotherapy in patients who had already gone through one unsuccessful round of traditional cancer treatment. The research found the pill, daraxonrasib, halted or reversed tumour progression by nearly a third compared to just 10 per cent in those given chemotherapy — and doubled survival time from less than seven months to roughly 13.

The trial results from U.S. Biotech company Revolution Medicines were published in the New England Journal of Medicine on Sunday and received a standing ovation at the American Society of Clinical Oncology (ASOC) annual meeting the same day.

Canadian medical oncologist Dr. Bishal Gyawali, an associate professor at Queen's University in Kingston, Ont., was among those in attendance. 

"It is the biggest breakthrough for pancreatic cancer ever," echoed Dr. Jennifer Knox, a medical oncologist specializing in pancreatic cancer at the Princess Margaret Cancer Centre in Toronto, who is also at the ASOC meeting.

"We haven't seen an improvement like this with any other treatments. There's been a lot of really exciting breakthroughs across oncology; none of them worked in pancreatic cancer. And so this is the game changer."

The "silent killer" shows few symptoms early on and is often caught far too late, leading to a merely 13 per cent five-year survival rate.

It's also stubbornly resistant to treatment, in part because by the time it's diagnosed, the cancer has typically spread beyond the pancreas — a small gland deep in the abdomen — and into other organs, such as the liver, lungs or abdominal wall.

A trial result showing a doubling of survival time for pancreatic cancer has "never happened" until now, Gyawali said, though he stressed the experimental pill is still considered a second-line treatment and not a cure.

"There are still miles to go, but it is exciting in the sense that, for the first time [for] such a lethal disease, we are seeing such good outcomes," he said.

Daraxonrasib works by targeting a faulty protein that leads to unchecked tumour growth, marking a radical new approach to cancer treatment. 

More than nine in 10 pancreatic cancer cases are driven by a mutation in the KRAS gene, which acts as an on-off switch for cells. The mutation produces an abnormal version of the KRAS protein, which remains stuck in "on" mode, sending never-ending signals for cells to grow and multiply.

"It is exciting that we could target this mutation for the first time and sort of break it," Gyawali said, calling the results "remarkable."

On social media, other physicians have also deemed the findings a "breakthrough" and a "historic moment."

"These results ​will change how scientists, clinicians and patients think about treatment for pancreatic cancer," the trial's principal investigator, Dr. Brian Wolpin of Harvard's Dana-Farber Cancer Institute, told Reuters.

The pill also appears to lead to fewer life-altering side effects, the research team found. Adverse events that led people to stop treatment occurred in 1.2 per cent of people in the daraxonrasib group, compared to 11 per cent of those in the chemotherapy group. 

However, a frequent and severe side effect of the drug has ⁠been a rash, which roughly 14 per cent of patients experienced.

Pancreatic cancer patient Menta "Steve" Wallace, from Houston, Texas, was one of those individuals. Still, the 74-year-old told Reuters he is "very pleased" with the overall results of daraxonrasib while participating in an additional, ongoing trial from Revolution Medicine that's testing the drug in earlier-stage disease and in combination with other treatments.

Wallace said his last scan showed his tumor had shrunk by nearly 50 per cent.

Daraxonrasib is the first in a new class of drugs called RAS(ON) inhibitors, which target various members of the RAS family of genes and their corresponding proteins. KRAS is one specific gene within the RAS family, which is found in a range of lethal human cancers. 

"It has been studied for decades, like 50 to 60 years, and it was thought to be undruggable," said Knox, the oncologist from Toronto.

But there's now hope that these promising findings could fuel the development of other pill-based RAS(ON) inhibitor treatments, not only for pancreatic cancer but other potentially deadly cancers as well.

"Lung cancer, colorectal cancer, biliary tract cancer, kidney cancers, gastric cancers — lots of cancers have mutations in RAS," Knox said.

"There's the potential to help all of those."

Daraxonrasib isn't yet approved in Canada or the U.S., though American patients can get treatment through an early access program authorized by the U.S. Food and Drug Administration.

So, when could the drug be available to Canadians?

More than 7,000 new cases of pancreatic cancer are diagnosed annually in Canada, according to the Canadian Cancer Society, and the disease kills upwards of 6,000 people each year.

Senior Health & Medical Reporter

Add some “good” to your morning and evening.

---

---